DE69714033T2 - Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten - Google Patents

Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten

Info

Publication number
DE69714033T2
DE69714033T2 DE69714033T DE69714033T DE69714033T2 DE 69714033 T2 DE69714033 T2 DE 69714033T2 DE 69714033 T DE69714033 T DE 69714033T DE 69714033 T DE69714033 T DE 69714033T DE 69714033 T2 DE69714033 T2 DE 69714033T2
Authority
DE
Germany
Prior art keywords
ras
lymphoizytes
cytitoxic
muted
generate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69714033T
Other languages
English (en)
Other versions
DE69714033D1 (de
Inventor
Jeffrey Schlom
Scott Abrams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Health NIH
Original Assignee
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Health NIH filed Critical National Institutes of Health NIH
Application granted granted Critical
Publication of DE69714033D1 publication Critical patent/DE69714033D1/de
Publication of DE69714033T2 publication Critical patent/DE69714033T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82Translation products from oncogenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4611T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/464454Enzymes
    • A61K39/464464GTPases, e.g. Ras or Rho
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69714033T 1996-04-19 1997-04-17 Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten Expired - Lifetime DE69714033T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63534496A 1996-04-19 1996-04-19
PCT/US1997/006470 WO1997040156A1 (en) 1996-04-19 1997-04-17 Mutated ras peptides for generation of cd8+ cytotoxic t lymphocytes

Publications (2)

Publication Number Publication Date
DE69714033D1 DE69714033D1 (de) 2002-08-22
DE69714033T2 true DE69714033T2 (de) 2003-02-13

Family

ID=24547410

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69714033T Expired - Lifetime DE69714033T2 (de) 1996-04-19 1997-04-17 Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten

Country Status (8)

Country Link
US (1) US8883448B2 (de)
EP (1) EP0895538B1 (de)
AT (1) ATE220718T1 (de)
AU (1) AU2734397A (de)
DE (1) DE69714033T2 (de)
DK (1) DK0895538T3 (de)
ES (1) ES2180045T3 (de)
WO (1) WO1997040156A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019112B1 (en) 1996-03-19 2006-03-28 University Of Virginia Patent Foundation Peptides recognized by melanoma-specific A1-, A2- and A3-restricted cytoxic lymphocytes, and uses therefor
EP0966480A2 (de) 1997-01-30 1999-12-29 The University Of Virginia Patent Foundation Cystein-reduzierte peptide, welche durch a3-limitierte zytotoxische lymphozyten erkannt werden, sowie anwendungen
GB2328689A (en) * 1997-08-27 1999-03-03 Norsk Hydro As Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer
GB9907860D0 (en) * 1999-04-07 1999-06-02 Smithkline Beecham Biolog Novel compounds
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
EP1581174B1 (de) 2002-12-16 2018-04-25 GlobeImmune, Inc. Impfstoffe auf hefebasis als immuntherapie
CN105999250B (zh) * 2011-05-24 2020-03-10 生物技术Rna制药有限公司 用于癌症的个体化疫苗
WO2013167136A1 (en) 2012-05-08 2013-11-14 Herlev Hospital Improving adoptive cell therapy with interferon gamma
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2015123532A1 (en) * 2014-02-16 2015-08-20 Globeimmune, Inc. Ras g12r immunotherapy for ras mutation-positive cancers
EP3201321A1 (de) * 2014-10-02 2017-08-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Verfahren zur isolierung von t-zellen mit antigenspezifizität gegen eine krebsspezifische mutation
AU2019226586A1 (en) * 2018-03-02 2020-10-15 Elicio Therapeutics, Inc. Compounds including a mutant KRAS sequence and a lipid and uses thereof
CN113631172A (zh) * 2019-01-25 2021-11-09 宾夕法尼亚大学理事会 用于靶向突变型ras的组合物和方法
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039948A (en) 1973-05-07 2000-03-21 The Ohio State University Method for treatment of antigenically modified polypeptides
US5643565A (en) 1985-09-20 1997-07-01 Chiron Corporation Human IL-2 as a vaccine adjuvant
EP0399001B1 (de) 1988-02-01 1994-07-27 Praxis Biologics, Inc. T-zellen-epitope als träger für einen konjugierten impfstoff
GB8924438D0 (en) 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
GB9103974D0 (en) 1991-02-26 1991-04-10 Norsk Hydro As Therapeutically useful peptides or peptide fragments
US5861372A (en) 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use

Also Published As

Publication number Publication date
ES2180045T3 (es) 2003-02-01
WO1997040156A1 (en) 1997-10-30
EP0895538A1 (de) 1999-02-10
AU2734397A (en) 1997-11-12
DE69714033D1 (de) 2002-08-22
DK0895538T3 (da) 2002-11-04
US8883448B2 (en) 2014-11-11
EP0895538B1 (de) 2002-07-17
US20100074945A1 (en) 2010-03-25
ATE220718T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
DE69714033T2 (de) Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten
CY1107706T1 (el) Πεπτιδια ανταγωνιστες καρκινοεμβρυονικου αντιγονου (cea)
DE69733610D1 (de) Interleukin-15 antagoniste
DE69324487D1 (de) Rezeptorbindende region des diphtherietoxius
AU4072397A (en) Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor
HUP9801826A2 (hu) HER-2/neu-fehérje intracelluláris doménje, és alkalmazása malignitások megelőzésére és kezelésére
NO923953L (no) Peptider
DE59807369D1 (de) Medizinische Bandage
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
ATE217795T1 (de) Saponin-antigen-konjugate und ihre verwendung
DK1210430T3 (da) MUC-1-afledte peptider
IT1196484B (it) Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
WO1997035021A3 (en) Prostate specific antigen oligo-epitope peptide
DE3764491D1 (de) Haardauerwellenmittel.
UA85365C2 (ru) Продукт конъюгирования цитокина для использования в противораковой терапии
PT1025849E (pt) Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
NO983177L (no) Anvendelse av 1-enantiomeren av centkroman til fremstilling av et farmasaytisk preparat for behandling eller profylakse av brystkreft
BR0110577A (pt) Decorina transgenicamente produzida
FR2804027B1 (fr) Utilisation d'anticorps monoclonaux anti-ferritines dans le traitement de certains cancers
DE3860354D1 (de) Neigungseinstell- und verstellvorrichtung fuer klapp-, lehnstuehle und aehnliche gegenstaende.
EP0836480A4 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität ausweisen und methoden für ihre herstellung und die verwendung derselben
BR0107547A (pt) Receptor
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf
SE9501512D0 (sv) Synthetic peptide-defined eptopes useful for vaccination against papillomavirus
MX9205978A (es) Nuevas proteinas inhibidoras de trombina de garrapatas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition